The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: A viewpoint

Hormones and Cancer

Volumn 1, Issue 2, 2010, Pages 63-70

  Rochefort, Henri ^a,b   Chalbos, Dany ^a,b  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Androgens; Breast and prostate carcinogenesis; Fatty acid synthase; Progestins

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; DNA; FATTY ACID SYNTHASE; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ARTICLE; BREAST CARCINOGENESIS; CANCER CELL; CELL DIVISION; COLONY FORMATION; DNA REPLICATION; FATTY ACID SYNTHESIS; GLYCOLYSIS; HORMONE SUBSTITUTION; HUMAN; LIPOGENESIS; MENOPAUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

BREAST NEOPLASMS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; LIPOGENESIS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID;

EID: 78649344908     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0009-7     Document Type: Article

References (77)

1. Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839.
2. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333.
3. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Current Opin Clin Nutr Metab Care 9:358-365.
4. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777.
5. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Current Opinion in Genetics and Development 18:54-61.
6. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nature Reviews Cancer 4:891-899.
7. Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523-4530.
8. Weiss L, Hoffmann GE, Schreiber R et al (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Biol Chem Hoppe-Seyler 367:905-912.
9. Anderson SM, Rudolph MC, Mc Manaman JL et al (2007) Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Breast Cancer Res 9:204-210.
10. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R (2004) Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues. Int J Oncol 24:1369-83.
11. Little JL, Kridel SJ (2008) Fatty acid synthase activity in tumor cells. Subcell Biochem 49:169-94 (review).
12. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Review Cancer 8:705-713.
13. Furuta E, Pai SK, Zhan R et al (2008) Fatty acid is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Research 68:1003-1111.
14. Moncur JT, Park JP, Memoli VA, Mohandas TK, Kinlaw WB (1998) The Spot 14 gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism. Proc Natl Acad Sci USA 95:6989-6994.
15. Sinilnikova OM, Ginolhac SM, Magnard C et al (2004) Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 25:2417-2424.
16. Moreau K, Dizin E, Ray H, Luquain C, Lefai E et al (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281:3172-3181.
17. Chalbos D, Chambon M, Ailhaud G et al (1987) Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923-9926.
18. Rochefort H, Chalbos D (1984) Progestin specific markers in human cell lines: biological and pharmacological applications. Mol Cell Endocrinol 36:3-10.
19. Joyeux C, Rochefort H, Chalbos D (1989) Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 4:681-686.
20. Amy CM, Williams-Ahlf B, Naggert J, Smith S (1990) Molecular cloning of the mammalian fatty acid synthase gene and identification of the promoter region. Biochem J 271:675-679.
21. Rolland V, Liepvre XL, Jump DB, Lavau M, Dugail IA (1996) GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes. Implication in the overactivity of FAS promoter in obese Zucker rats. J Biol Chem 271:21297-212302.
22. Yang YA, Morin PJ, Han WF et al (2002) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-137.
23. Chalbos D, Escot C, Joyeux C et al (1990) Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridisation. J Natl Cancer Inst 82:602-606.
24. Joyeux C, Chalbos D, Rochefort H (1990) Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 70:1438-1444.
25. Escot C, Joyeux C, Mathieu M, Maudelonde T, Pages A, Rochefort H, Chalbos D (1990) Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle. J Clin Endocrinol Metab 70:1319-1324.
26. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448-454.
27. Alo PL, Visca P, Marci A et al (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474-482.
28. Kuhajda FP, Piantadosi S, Pasternack GR (1989) Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636-641.
29. Heemers HV, Verhoeven G, Swinnen JV (2006) Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20:2265-2277.
30. Edgard G, Tang D, Rossi S et al (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5:253-261.
31. Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1-9.
32. Hisatake JI, Ikezoe T, Carey M et al (2000) Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494-5498.
33. Qiao S, Pennanen P, Nazarova N, Lou YR, Tuohimaa P (2003) Inhibition of fatty acid synthase expression by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol 85:1-8.
34. Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207-223.
35. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98(1):19-22.
36. Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB (1996) Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohisto-chemical and in situ hybridization study. Prostate 29:137-145.
37. Endogenous Sex Hormones and Prostate Cancer Collaborative Group (2008) A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-183.
38. Gottlieb B et al (2004) The androgen receptor gene mutations database (ARDB). Hum Mutat 23:527-533.
39. Lange EM et al (2008) The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet 53:220-226.
40. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808.
41. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM (2009) Increased expression of androgen receptor coregulator; MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 7:523-535.
42. Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552-556.
43. Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687-97.
44. Rochefort H, Sahla M, Chalbos D (2005) Progestins-induced genes and breast cancer risk: good or bad? In: Li JJ (ed) Hormonal carcinogenesis, vol 4. Springer, New York, pp 65-76.
45. Vignon F, Bardon S, Chalbos D, Rochefort H (1983) Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrin Metab 56:1124-1130.
46. Chambon M, Rochefort H, Vial HJ et al (1989) Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem 33:915-922.
47. Graham JD, Mote PA, Salagame U, van Dijk JH et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 50:3318-3326.
48. Beral V, the MWS group (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427.
49. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA (1998) A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci USA 95:5076-5081.
50. Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92:469-473.
51. Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93:3295-3298.
52. Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H (2007) Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 120(2):224-229.
53. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80-90.
54. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63 (1):132-139.
55. Anzick S et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965-968.
56. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19:2713-2735.
57. Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM (2009) Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 23:1135-1146.
58. Chalbos D, Haagensen D, Parish T et al (1987) Identification and androgen regulation of two proteins released by the T47D human breast cancer cells. Cancer Res 47:2782-2792.
59. Bao Y, Hunter L, Jenkins JR et al (2005) Zn_alpha2-glycoprotein, a lipid mobilizing factor is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:41-47.
60. Farmer P, Bonnefoi H, Becette V et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660-4671.
61. Chirala SS, Chang H, Matzuk M et al (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 100:6358-6363.
62. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
63. Fiorentino M, Zadra G, Palescandolo M et al (2008) Over-expression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 88:1340-1348.
64. Rossi S, Graner E, Febbo P, Weinstein L et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707-715.
65. Kuhajda FP, Jenner K, Wood FD et al (1994) Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379-6383.
66. Baron A, Migita T, Tang D et al (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91:47-53.
67. Puig T, Turrado C, Benhamú B, Aguilar H et al (2009) Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 15:7608-7615.
68. Little JL, Wheeler FB, Koumenis C, Kridel SJ (2008) Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 7:3816-3824.
69. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006) Prevention of BrCa1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467-1470.
70. Smith MR, Manola J, Kaufman DS et al (2004) Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569-1574.
71. Annicotte JS, Iankova I, Miard S et al (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26:7561-7574.
72. Tian WX (2006) Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 13(8):967-77 (review).
73. Khan N, Asim M, Afaq F, Abu Zaid M, Mukhtar H (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68:8555-8563.
74. Shin ES, Lee HH, Cho SY et al (2007) Genistein down regulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J Nutr 137:1127-1131.
75. Dang C-C, Audinot V, Papapoulos SE, Boutin JA, Löwik CWGM (2003) Peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962-967.
76. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077-3080.
77. Solimini NL, Luo J, Elledge SJ (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130:986-988.